Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with a specific reporting date of April 13, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Instrument | Transaction Type | Price per Share | Total Volume per Executive | Transaction Date | Exchange |
|---|---|---|---|---|---|
| Ordinary Shares (25p) | Acquisition (Share Reward Plan) | £17.7876 | 14 (7 partnership + 7 matching) | 2022-04-11 | London Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents routine compliance notifications for share acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed under the Company's Share Reward Plan, involving both partnership shares and matching shares.
Important Facts for Investors
- Insider Activity: Ten senior executives and one associated person acquired shares on April 11, 2022.
- Participants: Transactions were made by the CEO (Ms E Walmsley), President of Vaccines (Mr R Connor), Chief People Officer (Ms D Conrad), Group General Counsel (Mr J Ford), SVP Global Communications (Ms S Jackson), her PCA (Mr D Jackson), Chief Strategy Officer (Mr D Redfern), President of Pharmaceuticals Supply Chain (Mr R Simard), President of Global Affairs (Mr P Thomson), CEO of ViiV Healthcare (Ms D Waterhouse), and Company Secretary (Ms V Whyte).
- Transaction Structure: Each individual acquired 14 Ordinary Shares total, split evenly between 7 partnership shares and 7 matching shares.
- Valuation: All shares were acquired at a uniform price of £17.7876 per share.
- Scope: This filing is a regulatory disclosure of specific transactions and does not reflect broader company performance.